Development of 2D-LC/MS/MS Bioanalytical Method for Quantitative Determination of Insulin Glargine in Human Plasma

Recently, LC/MS/MS has been applied for quantitative analysis of glargine and other insulin analogues, because it enables to distinguish human insulin and recombinant analogues as well as their metabolites. The American Diabetes Association has recommended the sensitivity of bioassay to achieve an LLOQ of 70 pg/mL, which is challenging to the current LC-MS systems. The bioassay reported always require tedious solid phase extraction (SPE) for clean up before injecting into the LC/MS/MS. This motivated this study, aiming at developing a high sensitivity method on the latest LCMS-8060 to determine quantitatively insulin glargine in human plasma with lesser sample preparation steps. We describe a newly developed 2D-LC/MS/MS method for high sensitivity quantitation of insulin glargine spiked in human plasma without SPE clean up.

Content Type:
Paper
Document Number:
PO-CON1645E
Product Type:
Mass Spectrometry, Liquid Chromatograph-Mass Spectrometry
Keywords:
Insulin Glargine, Human Plasma, The American Diabetes Association, bioassay, 2D-LC/MS/MS, Pharmaceutical, Life Science, Healthcare, LCMS-8060, 2D-LC/MS/MS
Language:
English
File Name:
apo116045.pdf
File Size:
260kb

View Article

For Research Use Only. Not for use in diagnostic procedures.

This page may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

Top of This Page

Please select your country or region.

Transferring to the local website of your country or region.

Transfer to
https://www.ssi.shimadzu.com/